Optimization and Evaluation of Beclomethasone Dipropionate Micelles Incorporated into Biocompatible Hydrogel Using a Sub-Chronic Dermatitis Animal Model

Assem, M. A.; Khowessah, Omneya Mohammed; Ghorab, Dalia

doi:10.1208/s12249-019-1355-6

Cited by 14 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Assem et al (100) developed polymeric micelles of beclomethasone dipropionate and incorporated them into biocompatible hydrogel. The formulation was evaluated using sub-chronic dermatitis animal model.…”

Section: Micellesmentioning

confidence: 99%

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

et al. 2021

View full text Add to dashboard Cite

Globally, the prevalence of Atopic dermatitis (AD) is significantly increasing and affecting around 20% of population including children. Complex interactions amongst abnormality in epidermal barrier function, environment, infectious agents and immunological defects are considered as key factors in the pathogenesis of AD. Although the role of oxidative stress has been studied in some skin diseases, investigation of the same in AD is intermittent. Calcineurin inhibitors and/or topical corticosteroids are currently available; however, it causes atrophy of the skin, burning sensation, and systemic side effects which leads to poor patient compliance. These limitations provoke the strong need to develop an innovative approach in managing AD. Nanomaterials for effective drug delivery to skin conditions such as AD have attracted a lot of attention owing to its ability to encapsulate, protect, and release the cargo at the diseased skin site. However, there are lots of unmet challenges especially in terms of development of non-toxic formulations and clinical translation of established nanomedicines in the form of accessible products. Numerous formulations have emerged as carrier for poorly soluble and permeable drugs, viz., lipidic, polymeric, metal, silica, liposomes, hydrocarbon gels and this field is evolving. This review is intended to provide an insight incidences associated with pathophysiology of AD and challenges with existing treatments of AD. Focus is kept on reviewing current development and emerging nanomedicines for effective treatment of AD. The review also inculcates merits of several nanomedicines in overcoming challenges of existing products and its future implications.

show abstract

Section: Micellesmentioning

confidence: 99%

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A comparative study of the viscosity and dermal drug deposition between the prepared hydrogel and the marketed Beclozone ® cream was conducted. In vivo histopathological analysis of the mixed micelle hydrogel and Beclozone ® demonstrated successful sub-chronic dermatitis treatment in an animal model by the prepared hydrogel within (6 days) as compared to Beclozone ® (12 days), thus ensuring enhanced patient compliance and lesser adverse effects [ 92 ].…”

Section: Nanocarrier-mediated Delivery Of Tcs In Psoriasis and Admentioning

confidence: 99%

“… [ 91 ] Polymeric micelles Beclomethasone dipropionate Thin-film hydration technique Pluronic F127 (PL-F127); Synperonic PE/P84 (P84); Pluronic L121 (PL-L121); acetone; distilled water Better skin biocompatibility, minimal systemic drug circulation, and early tissue regeneration than marketed formulations. [ 92 ] Polymeric microspheres Clobetasol propionate Emulsion solvent evaporation technique PLGA; polyvinyl alcohol; dichloromethane Higher drug release than the marketed cream product. [ 95 ] Polymeric microsponges Betamethasone The quasi-emulsion solvent diffusion method Eudragit RS 100; dichloromethane; ethanol; polyvinyl alcohol; Carbopol; triethanolamine; water In vitro drug release studies reported 76% of drug release in a controlled manner.…”

Section: Nanocarrier-mediated Delivery Of Tcs In Psoriasis and Admentioning

confidence: 99%

Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis—a systematic review

Shetty

Sherje

2021

J Mater Sci: Mater Med

View full text Add to dashboard Cite

Atopic dermatitis (AD) and psoriasis are highly prevalent, complex, chronic inflammatory skin diseases that immensly affect the patient’s quality of life. While there is no definitive cure for these conditions, suppressive medications aim at managing the symptoms of these diseases. The application of emollients accompanied by symptomatic anti-inflammatory therapy consisting of topical corticosteroids (TCS) is extensively employed for controlling the symptoms among general practitioners making this therapeutic class an indispensable pillar of dermatotherapeutics. The first TCS, hydrocortisone (HC) introduced in the early 1950s led to the development of different steroidal moieties of varying potencies by inducing chemical modifications to the basic steroid structure. The wide spectrum of the available range of formulations and potency provides flexibility to treat all patient groups, different phases of the diseases, and different anatomical sites. Conventional TCS therapy suffers from drawbacks such as low drug permeation and retention rate. Thus, novel nanoformulations have been developed to overcome these problems. This review provides an insight into the current state of nanocarrier-mediated topical delivery of corticosteroids monotherapy and combination therapy with special emphasis on targeting psoriasis and AD.

show abstract

“…Faster tissue regeneration comparing to the commercial product; Controlled drug release; Controlled side effects [78] Hydrocortisone Monomethyl poly(ethylene glycol)-poly( -caprolactone) micelles incorporated in Carbopol hydrogel.…”

Section: Hydrogels For Bioactive Compounds' Deliverymentioning

confidence: 99%

“…This corticosteroid was incorporated in micelles, formed by a mix of different ratios of Pluronic L‐121 with Poloxamer 84 or Pluronic F127 to be further applied to an hydroxypropyl methyl cellulose hydrogel. [ 78 ] Comparing to the commercially available cream, the formulated hydrogel provided faster tissue regeneration and local controlled beclomethasone dipropionate delivery, minimizing systemic side effects.…”

Section: Hydrogels For Atopic Dermatitismentioning

confidence: 99%

Hydrogels: A Promising Vehicle for the Topical Management of Atopic Dermatitis

Barbosa

Torres

Lima

2021

Advanced Therapeutics

View full text Add to dashboard Cite

Atopic dermatitis (AD) is an inflammatory skin disease with a high worldwide prevalence. AD is characterized by fluctuating and recurrent eczematous lesions and intense itch, being associated with high physical and psychological impact leading to disturbed sleep quality, anxiety, and depression. Most of the patients have mild to moderate forms of atopic dermatitis and topical therapies (emollients, corticosteroids, calcineurin, and phosphodiesterase 4 inhibitors) are the mainstay of therapy for these patients. Hydrogels are explored in the field of cutaneous application and have proven to be a good solution as a topical vehicle for atopic dermatitis, due to their high water content, improved drug delivery, responsiveness to stimuli and versatility in terms of preparation and drug-loading, representing a good alternative to regular ointments or creams. This review highlights some of the atopic dermatitis characteristics and the use of hydrogels in the management of this disease. An outline of hydrogels as drug delivery systems for bioactive compounds is discussed, as well as their major advantages and drawbacks when compared to other galenic forms, and also an overview of clinical trials and patents engaged in the past 20 years.

show abstract

Optimization and Evaluation of Beclomethasone Dipropionate Micelles Incorporated into Biocompatible Hydrogel Using a Sub-Chronic Dermatitis Animal Model

Cited by 14 publications

References 41 publications

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

Emerging Nanomedicines for the Treatment of Atopic Dermatitis

Nano intervention in topical delivery of corticosteroid for psoriasis and atopic dermatitis—a systematic review

Hydrogels: A Promising Vehicle for the Topical Management of Atopic Dermatitis

Contact Info

Product

Resources

About